CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 17, 2018
- Accepted in final form September 12, 2018
- First Published November 7, 2018.
Author Disclosures
- Magnus Gisslén, MD, PhD,
- Amanda Heslegrave, PhD,
- Elena Veleva, BSc,
- Aylin Yilmaz, MD, PhD,
- Lars-Magnus Andersson, MD, PhD,
- Lars Hagberg, MD, PhD,
- Serena Spudich, MD, MA,
- Dietmar Fuchs, MSc, PhD,
- Richard W. Price, MD and
- Henrik Zetterberg, MD, PhD
- Magnus Gisslén, MD, PhD,
1.Gilead Sciences; 2. BMS; 3. Janssen; 4. MSD
NONE
1. Gilead, speaker honoraria; 2. BMS, speaker honoraria; 3. Janssen, speaker honoraria
1. HIV&Virology News, Editor, 2016; 2. AIDS Research and Therapy, editorial adv board, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Gilead; 2. Janssen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amanda Heslegrave, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elena Veleva, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aylin Yilmaz, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lars-Magnus Andersson, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lars Hagberg, MD, PhD,
NONE
NONE
NONE
Infectious Diseases, Associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Serena Spudich, MD, MA,
NONE
NONE
NONE
Guest Editor, single issue, Seminars in Neurology, 2014. Section Editor, Current HIV/AIDS Reports, 2015, 2016. Editorial Panel, Journal of Virus Eradication, 2015, 2016. Guest Editor, single issue, AIDS, 2018.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Viiv Healthcare, Inc. provides study medications for a study that I co-chair through the AIDS Clinical Trials Group.
NIH grants: R01 NS084911, PI, 2013-present, P01 MH094177, site PI, 2013- 16, R01 MH106466, PI, 2016-present, R21MH118109, PI, 2018-present, R21MH118023, PI, 2018-present, R21MH110260, PI, 2016-present, U24NS107136, PI, 2018-present.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dietmar Fuchs, MSc, PhD,
NONE
NONE
NONE
Pteridines, Chief Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Richard W. Price, MD and
NONE
NONE
NONE
NONE
NONE
UpToDate,Wolters Klumer Health, HIV-associated neurocognitive disorders, 2 parts; 2016- present.
NONE
NONE
NONE
NONE
NONE
NONE
NIDA, P01DA026134, Project PI, 2008 - 2011. NIMH, R01-MH62701, PI, 2000 - 2010. NIMH, R21-MH083520, PI, 2008 - 2010. NIMH, U01-MH083545, Consultant, 2008 -2013. NIMH, R01MH081772, Co-I, 2008 -2013. NIMH/NIAID, U01-AI068641, Co-Chair Neurology substudy Protocol, 2009-2010. NIMH/NIAID, U01-AI38858, Co-Chair AACTG study A5199, 2003 - 2011. NIMH, P01 MH094177, Project PI, subcontract from University of North Carolina, 2011-2016. NINDS, R01 1R01NS094067, 2015-2020, PI. NIAID/NIMH, U01AI131295 subaward from Case Western University 2018-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henrik Zetterberg, MD, PhD
HZ has served at advisory boards for Roche Diagnostics and Eli Lilly.
NONE
NONE
Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor Molecular and Cellular Neuroscience, Editor Scandinavian Journal of Clinical and Laboratory Investigation, Editor
NONE
NONE
NONE
NONE
NONE
HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.
NONE
NONE
(1) Swedish State Support for Clinical Research (ALFGBG- 144341) and (2) the Knut and Alice Wallenberg Foundation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Infectious Diseases (M.G., A.Y., L.-M.A., L.H.), Institute of Biomedicine, the Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Molecular Neuroscience (A.H., E.V., H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute at UCL (A.H., E.V., H.Z.), London, United Kingdom; Department of Neurology and Center for Neuroepidemiology and Clinical Neurological Research (S.S.), Yale University, New Haven, CT; Division of Biological Chemistry (D.F.), Biocenter, Medical University of Innsbruck, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital; and Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
- Correspondence
Dr. Gisslén magnus.gisslen{at}gu.se
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.